FDA Clearing Backlog Of Post-Marketing Studies, But Progress May Slow
This article was originally published in The Pink Sheet Daily
Executive Summary
While more than half of the post-marketing commitment backlog from 2007 and earlier has been cleared from FDA’s books, but the portion of “delayed” studies has remained consistent.